3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
Oxaliplatin
7
Fluorouracil
7
Leucovorin
6
pembrolizumab
4
Paclitaxel
4
Capecitabine
4
Radiotherapy
3
Radiation
3
Nivolumab
3
Cisplatin
3
zimberelimab
2
tislelizumab
2
durvalumab
2
Trastuzumab
2
Taxes
2
Levoleucovorin
2
Irinotecan
2
zanidatamab
1
tucatinib
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab deruxtecan
1
spartalizumab
1
quemliclustat
1
obinutuzumab
1
naptumomab estafenatox
1
lenvatinib
1
futibatinib
1
dehydroftorafur
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Adenocarcinoma Of Esophagus
×
zimberelimab
×
Clear all
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled
NCT05568095
2026-06-02
STAR-221
Arcus Biosciences, Inc.
Phase 3
Active not recruiting
1,040 enrolled